These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 10627638

  • 21. Unrelated donor bone marrow transplantation in Fanconi anaemia: the Leiden experience.
    Zwaan CM, Van Weel-Sipman MH, Fibbe WE, Oudshoorn M, Vossen JM.
    Bone Marrow Transplant; 1998 Mar; 21(5):447-53. PubMed ID: 9535036
    [Abstract] [Full Text] [Related]

  • 22. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K.
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [Abstract] [Full Text] [Related]

  • 23. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
    Al-Kasim FA, Thornley I, Rolland M, Lau W, Tsang R, Freedman MH, Saunders EF, Calderwood S, Doyle JJ.
    Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
    [Abstract] [Full Text] [Related]

  • 24. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 25. Partially mismatched related donor bone marrow transplantation as salvage for patients with AML who failed autologous stem cell transplant.
    Godder KT, Mehta J, Chiang KY, Adams S, van Rhee F, Singhal S, Higgins-Smith K, O'Neal W, DeRienzo S, Henslee-Downey JP.
    Bone Marrow Transplant; 2001 Dec; 28(11):1031-6. PubMed ID: 11781612
    [Abstract] [Full Text] [Related]

  • 26. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse.
    Chiang KY, Weisdorf DJ, Davies SM, Enright H, Kersey JH, McGlave PB, Miller W, Ramsay NK, Steinbuch M, Wagner JE, Blazar BR.
    Bone Marrow Transplant; 1996 Jan; 17(1):39-42. PubMed ID: 8673052
    [Abstract] [Full Text] [Related]

  • 27. Unrelated cord blood transplant experience by the pediatric blood and marrow transplant consortium.
    Yu LC, Wall DA, Sandler E, Chan KW, Grayson G, Kletzel M.
    Pediatr Hematol Oncol; 2001 Jun; 18(4):235-45. PubMed ID: 11400647
    [Abstract] [Full Text] [Related]

  • 28. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
    Tan PL, Wagner JE, Auerbach AD, Defor TE, Slungaard A, Macmillan ML.
    Pediatr Blood Cancer; 2006 May 01; 46(5):630-6. PubMed ID: 16078221
    [Abstract] [Full Text] [Related]

  • 29. Matched-pair analysis comparing allogeneic PBPCT and BMT from HLA-identical relatives in childhood acute lymphoblastic leukemia.
    Vicent MG, Madero L, Ortega JJ, Martinez A, Gomez P, Verdeguer A, Badell I, Muñoz A, Olive T, Maldonado MS, Bureo E, Cubells J, Diaz MA, Spanish Working Party for BMT in Children (GETMON).
    Bone Marrow Transplant; 2002 Jul 01; 30(1):9-13. PubMed ID: 12105771
    [Abstract] [Full Text] [Related]

  • 30. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.
    Min CK, Kim DW, Lee JW, Han CW, Min WS, Kim CC.
    Haematologica; 2001 Mar 01; 86(3):303-10. PubMed ID: 11255278
    [Abstract] [Full Text] [Related]

  • 31. Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy.
    Arranz R, Otero MJ, Ramos R, Steegmann JL, Lamana ML, Tomás JF, de la Cámara R, Figuera A, Vázquez L, Fernádez-Rañada JM.
    Bone Marrow Transplant; 1994 Apr 01; 13(4):383-7. PubMed ID: 8019461
    [Abstract] [Full Text] [Related]

  • 32. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
    Schots R, Van Riet I, Ben Othman T, Trullemans F, De Waele M, Van Camp B.
    Bone Marrow Transplant; 2001 Nov 01; 28(10):917-22. PubMed ID: 11753544
    [Abstract] [Full Text] [Related]

  • 33. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y, Suzuki R, Kuwatsuka Y, Yasuda T, Takahashi T, Tsujimura A, Sugimoto K, Oba T, Terakura S, Atsuta Y, Murata M, Ito M, Kodera Y, Miyamura K.
    Biol Blood Marrow Transplant; 2008 Jan 01; 14(1):43-9. PubMed ID: 18158960
    [Abstract] [Full Text] [Related]

  • 34. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
    Gaziev D, Galimberti M, Polchi P, Angelucci E, Giardini C, Baronciani D, Andreani M, Persini B, Erer B, Sodani P, Manna M, Nicolini G, Visani G, Lucarelli G, AIEOP.
    Bone Marrow Transplant; 2002 Jan 01; 29(1):1-8. PubMed ID: 11840137
    [Abstract] [Full Text] [Related]

  • 35. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun 01; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 36. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
    Byrne JL, Stainer C, Cull G, Haynes AP, Bessell EM, Hale G, Waldmann H, Russell NH.
    Bone Marrow Transplant; 2000 Feb 01; 25(4):411-7. PubMed ID: 10723585
    [Abstract] [Full Text] [Related]

  • 37. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G.
    Haematologica; 1995 Feb 01; 80(4):300-4. PubMed ID: 7590497
    [Abstract] [Full Text] [Related]

  • 38. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R.
    Bone Marrow Transplant; 2000 May 01; 25(10):1021-8. PubMed ID: 10828860
    [Abstract] [Full Text] [Related]

  • 39. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
    Martino R, Caballero MD, de la Serna J, Díez-Martín JL, Urbano-Ispízua A, Tomás JF, Odriozola J, León A, Canals C, San Miguel J, Sierra J.
    Bone Marrow Transplant; 2002 Jul 01; 30(2):63-8. PubMed ID: 12132043
    [Abstract] [Full Text] [Related]

  • 40. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
    Ghavamzadeh A, Iravani M, Ashouri A, Mousavi SA, Mahdavi N, Shamshiri A, Hadjibabaie M, Namdar R, Nedaeifard L, Ghaffari H, Alimoghaddam K.
    Biol Blood Marrow Transplant; 2008 Mar 01; 14(3):301-8. PubMed ID: 18275896
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.